Quicksilver Scientific Ultra Binder®: What the Research Shows About GI Binding Ingredients & Detox Claims

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

Quicksilver Scientific® Ultra Binder® is a multi-ingredient GI binder supplement marketed as a broad-spectrum “toxin binder” for detoxification support. Khang Pharmacy carries two current formulations: the Ultra Binder® Powder (120g) and the Ultra Binder® Capsules (120 capsules). Their ingredient profiles differ; both are reviewed here.

This article reviews what the published evidence actually supports for each ingredient, distinguishes acute toxicology evidence from chronic “detox” claims, and is explicit about what has not been established for the finished Ultra Binder® products. Consumer “detox” terminology is frequently used in ways that exceed the available clinical evidence; a pharmacist’s role is to help patients understand that distinction.

Supplement Facts — Ultra Binder® Powder (120g)

Serving size: 4 g (1 teaspoon) | Servings per container: 30 | Suggested use: Mix 1 teaspoon (4 g) in 8 oz of water once daily. Take away from meals and medications. Not intended for long-term daily use without practitioner guidance.

† Proprietary thiol-functionalized silica. Other ingredients: None. Tested soy protein free, gluten free, non-GMO, allergen-free. cGMP Certified.

⚠ Allergy Warning: Contains Shellfish (Chitosan is derived from crustacean shells). Do not use if you have a known shellfish allergy.

Supplement Facts — Ultra Binder® Capsules (120 Capsules)

Serving size: 1.8 g (4 capsules) | Servings per container: 30 | Suggested use: Take 4 capsules with 8 oz of water once daily, or as directed by a healthcare professional. Take 30 minutes before or 2 hours after meals or medications.

† Proprietary thiol-functionalized silica. Other ingredients: Plant-derived cellulose capsule.

⚠ Allergy Warning: Contains Shellfish (High Density Chitosan is derived from crustacean shells). Do not use if you have a known shellfish allergy. Manufactured in a facility that may also process tree nuts, soy, and dairy.

What the Evidence Does — and Does Not — Establish

• Human RCT evidence — specific to purified zeolite and lead exposure: Two randomized trials have evaluated purified clinoptilolite zeolite preparations: one demonstrating reduced enteral lead uptake in healthy volunteers using a specific purified G-PUR preparation, and one in patients with diagnosed lead poisoning using zeolite tablets. These findings reflect the specific purified zeolite preparations studied — not the zeolite contained in Ultra Binder®’s proprietary blend at undisclosed concentrations.
• Established (clinical toxicology guideline): Activated charcoal is addressed in a clinical toxicology position paper for selected acute oral poisonings, depending on the substance, timing, and clinical circumstances. It is not recommended for routine administration to all poisoned patients and has no established role in chronic environmental “detoxification.”
• Preclinical/mechanistic only: Chitosan’s adsorption of mycotoxins and bile acids, IMD’s thiol-mercury binding chemistry, sodium bentonite clay’s metal adsorption, and PectaSol-C®’s heavy-metal binding properties have been described in laboratory, preclinical, or limited early clinical settings. Published human RCT evidence for these effects specifically within the Ultra Binder® finished product has not been identified.
• Not established: That either Ultra Binder® product reduces body burden of heavy metals, mycotoxins, pesticides, or other environmental chemicals in healthy adults. The consumer “detox” framing — including broad claims about toxin burden reduction and symptom relief — is not supported by the current evidence base for these finished products.

What “Gastrointestinal Binding” Actually Means

GI binders work in the gastrointestinal tract: they bind certain substances present in the gut, reducing their absorption into the bloodstream or interrupting their reabsorption through enterohepatic recirculation. This is a real and clinically meaningful mechanism for specific applications — most clearly established in acute poisoning management and specific documented exposure contexts.

GI adsorption ≠ systemic chelation ≠ demonstrated reduction of body burden. Removing a substance from the gut before it is absorbed is mechanistically distinct from removing accumulated material from tissues, blood, or organs. The latter requires different evidence — specifically, human trials demonstrating measurable reductions in body burden (e.g., blood, urine, or tissue levels) in the target population. That evidence does not currently exist for Ultra Binder® as a finished product.

Documented heavy metal exposure, lead poisoning, mycotoxin illness, or other toxic exposures are medical conditions requiring appropriate clinical evaluation — not self-directed supplementation.

Ingredient-by-Ingredient Evidence Review

1. Zeolite (Clinoptilolite) [Human RCT evidence — specific to purified zeolite preparations and lead exposure]

Clinoptilolite is a naturally occurring aluminosilicate mineral with a crystalline structure capable of ion exchange and adsorption of certain cations. The human RCT evidence below is specific to purified clinoptilolite preparations studied in lead exposure contexts — not the zeolite in Ultra Binder®’s undisclosed-concentration proprietary blend.

• HUMAN RCT: Samekova K et al. (PMID: 34285282) demonstrated in 42 healthy adults that purified clinoptilolite tuff (G-PUR) reduced enteral uptake of a stable ²⁰⁴Pb tracer by approximately 90% versus placebo. This establishes a specific GI lead-binding effect under controlled conditions for a specific purified preparation — not generalized heavy metal removal from the body or removal of accumulated lead from tissues.
• HUMAN RCT: Teimouri S et al. (PMID: 40487907) randomized 80 patients with documented mild-to-moderate lead poisoning; the zeolite-plus-standard-treatment group had lower serum lead after two weeks than the standard-treatment-only group. The investigators described zeolite as showing promise as an adjunct therapy. This was a specific clinical population with diagnosed lead poisoning using zeolite tablets — not Ultra Binder®. These results do not establish that the zeolite within Ultra Binder®’s proprietary blend produces equivalent effects.
• What this evidence does not establish: That Ultra Binder® is an appropriate intervention for diagnosed lead poisoning or any other documented metal exposure; removal of accumulated metals from tissues or organs; or efficacy for mercury, arsenic, cadmium, mycotoxins, or other substances beyond the specific lead-exposure contexts studied.

2. Activated Charcoal [Acute toxicology guideline use only — not established for chronic environmental detox]

Activated charcoal is a highly porous carbon material with a large surface area that can adsorb a broad range of organic compounds. It is addressed in clinical toxicology position statements for selected acute oral poisonings.

• The AACT/EAPCCT position paper states that single-dose activated charcoal may be considered for selected potentially toxic oral ingestions of substances known to adsorb to charcoal, generally within one hour, when the airway is intact or protected. Routine administration is not recommended; evidence demonstrating improved clinical outcomes is stated to be lacking.
• Activated charcoal does not adsorb iron, lithium, lead, or arsenic — substances prominent in detox supplement marketing.
• What this evidence does not establish: A role for activated charcoal in chronic supplementation for environmental chemical reduction, generalized “toxin” removal, or symptom management in healthy adults.
• Drug interaction note: activated charcoal adsorbs medications non-selectively. See Safety section below.

3. Chitosan / High Density Chitosan

Chitosan is a polysaccharide derived from crustacean shells. Its positively charged structure can interact with bile acids and certain negatively charged compounds in the GI tract.

• Chitosan’s bile acid binding properties have been studied in the context of cholesterol management; this is the best-supported human application.
• Mycotoxin adsorption by chitosan has been described in laboratory settings. Human clinical trial evidence specifically demonstrating clinically meaningful mycotoxin removal through chitosan supplementation in routine consumer populations has not been identified.
• Evidence level for mycotoxin binding: PRECLINICAL / MECHANISTIC. Mechanism is plausible; human efficacy is not established.

4. IMD — Silica Extract (Thiol-Functionalized Silica, Proprietary)

IMD is Quicksilver Scientific’s proprietary thiol-functionalized silica. Thiol (–SH) groups can bind certain metals, including mercury, through sulfhydryl interactions.

• This chemistry provides mechanistic plausibility but does not establish clinical efficacy or safety for IMD as a supplement ingredient at the undisclosed dose present in the proprietary blend.
• Independent published human RCT evidence evaluating IMD specifically for mercury or metal reduction has not been identified.
• Evidence level: MECHANISTIC. The chemistry is real; clinical detoxification efficacy is not established by independent published evidence.

5. Sodium Bentonite Clay

Sodium bentonite is a phyllosilicate clay with adsorptive capacity for certain cations and organic molecules. Mycotoxin and heavy metal adsorption by bentonite clays have been described in preclinical and animal settings; robust human RCT evidence for clinically meaningful toxin reduction in healthy adults through bentonite supplementation is limited.

• Evidence level: PRECLINICAL / MECHANISTIC for toxin-binding claims in routine supplementation contexts.

6. Fibregum™ Bio (Gum Arabic) — Powder Only

Gum Arabic (acacia fiber) is a prebiotic soluble fiber with a well-established safety profile. Its inclusion supports gut health and bowel regularity during binder use — a practical rationale. Prebiotic effects and modest postprandial glucose-modulating properties have been studied in humans; this evidence is for gum Arabic as a dietary fiber, not as a toxin binder.

7. PectaSol-C® Modified Citrus Pectin — Capsules Only

PectaSol-C® is a low-molecular-weight modified citrus pectin studied in some early clinical trials for heavy metal excretion and galectin-3 modulation. Early pilot studies have reported increased urinary excretion of certain metals; these are small, preliminary trials and do not establish that PectaSol-C® within Ultra Binder®’s proprietary blend at undisclosed concentration produces equivalent effects.

• Evidence level: Preliminary/pilot — PectaSol-C® has more published human data than some other ingredients in this formula, but findings remain preliminary and should not be treated as established clinical efficacy for the compound finished product.

8. BioAloe® / BiAloe® Aloe Vera Leaf

Registered trademark aloe vera ingredients included to support GI mucosal integrity alongside the binding blend — a practical and defensible rationale. This role is analogous to demulcent botanical use in prior formulations.

Important Safety and Use Considerations

• Timing (powder): Mix 1 tsp in 8 oz water; take away from meals and medications per manufacturer labeling. Timing (capsules): Take 4 capsules with 8 oz water; take 30 minutes before or 2 hours after meals or medications.
• Shellfish allergy: Both products contain chitosan derived from crustacean shells. Do not use if you have a known shellfish allergy.
• Hydration and bowel regularity: Adequate water intake and normal bowel regularity are important during GI binder use. Constipation should be addressed promptly.
• Not for long-term daily use without practitioner guidance (per manufacturer labeling of the powder).
• Pregnancy: Consult a physician before use. The capsule product carries a Prop 65 notice regarding lead exposure in California.
• Documented toxic exposure: If you have documented or suspected heavy metal exposure, mycotoxin illness, or other toxic exposure, this requires medical evaluation — not self-directed supplementation.

Who May Consider Ultra Binder®?

• Individuals using a practitioner-supervised GI binding protocol after appropriate clinical evaluation, where the practitioner has determined that a dietary GI binder is appropriate for their specific situation
• Those working with a functional medicine or integrative practitioner who has reviewed their clinical history and identified a specific rationale for GI binding support
• Not appropriate for self-directed use to address generalized “toxin burden,” nonspecific symptoms, or as a first-line response to suspected toxic exposure without medical evaluation
• Important: Documented heavy-metal poisoning or other toxic exposure requires medical and toxicology evaluation and evidence-based management. Ultra Binder® should not be considered a substitute for established treatment of diagnosed metal toxicity.

Selected Key References

1. HUMAN RCT Samekova K, Firbas C, Irrgeher J, et al. Concomitant oral intake of purified clinoptilolite tuff (G-PUR) reduces enteral lead uptake in healthy humans. Sci Rep. 2021;11(1):14796. PMID: 34285282.
   Randomized, double-blind, placebo-controlled trial in 42 healthy adults. Purified G-PUR clinoptilolite reduced enteral ²⁰⁴Pb tracer uptake by ~90% versus placebo. Establishes GI lead-binding for this specific purified preparation under controlled conditions. Does not establish equivalent effects for the zeolite within Ultra Binder®’s proprietary blend, nor efficacy for metals other than lead.
2. HUMAN RCT Teimouri S, Deravi N, Khazaei A, et al. Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial. 2025. PMID: 40487907.
   Randomized clinical trial; 80 patients with documented mild-to-moderate lead poisoning. Zeolite tablets added to standard treatment associated with lower serum lead at 2 weeks versus standard treatment alone. Authors described findings as promising for adjunct use. Studied zeolite tablets in a diagnosed-poisoning clinical population — not Ultra Binder®. Does not establish Ultra Binder® as an appropriate intervention for diagnosed lead poisoning.
3. CLINICAL TOXICOLOGY GUIDELINE Chyka PA, Seger D, Krenzelok EP, Vale JA; AACT/EAPCCT. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61–87. PMID: 15822758.
   AACT/EAPCCT position paper. Single-dose activated charcoal may be considered for selected acute oral ingestions of adsorbing substances, generally within one hour, with intact or protected airway. Routine administration not recommended; evidence of improved clinical outcomes stated to be lacking. Does not adsorb iron, lithium, lead, or arsenic. Evidence applies to acute poisoning management only and does not support chronic supplementation for environmental chemical reduction.
4. PRECLINICAL / MECHANISTIC Chitosan — bile acid binding and mycotoxin adsorption described in laboratory and in vitro settings. No published human RCT establishing clinically meaningful mycotoxin removal through chitosan supplementation in routine consumer populations has been identified.
   Plausible mechanism; human efficacy for mycotoxin removal is not established.
5. PRECLINICAL / MECHANISTIC IMD (thiol-functionalized silica) — thiol–metal binding chemistry described in the chemical literature. Independent published human RCT evidence for IMD as a dietary supplement ingredient has not been identified.
   Binding chemistry provides mechanistic plausibility; clinical detoxification efficacy as a supplement ingredient is not established by independent published evidence.

Pharmacist’s Perspective

As a PharmD, the most important thing I can offer patients considering Ultra Binder® is clarity about what the evidence actually supports — and what it does not. The consumer detox category is saturated with language that implies clinical evidence where primarily mechanistic or preclinical data exists.

What I find clinically grounded in this formula: the zeolite GI lead-binding evidence (Samekova et al., PMID: 34285282; Teimouri et al., PMID: 40487907) demonstrates a real mechanism for specific purified preparations in specific lead-exposure contexts. The key distinction I make with patients: those studies evaluated specific purified zeolite preparations — not the zeolite within Ultra Binder®’s multi-ingredient proprietary blend at undisclosed concentration. The activated charcoal has an acute toxicology position-paper evidence base that does not transfer to chronic supplementation. IMD’s thiol-metal chemistry is real; clinical efficacy as a supplement ingredient is not independently established.

I do not recommend Ultra Binder® as an intervention for diagnosed metal toxicity or any other documented toxic exposure — those situations require medical evaluation and evidence-based clinical management. My recommendation is limited to patients in practitioner-supervised protocols where a clinician has reviewed their history and identified a specific rationale. For everyone else, I have a direct conversation about what the evidence actually shows before they spend money in this category. Free PharmD consultation: (408) 622-8068.

Frequently Asked Questions

Q: Does Ultra Binder® remove heavy metals from my body?
A: The zeolite component has published evidence for specific purified preparations reducing GI absorption of lead under controlled conditions. This is different from removing accumulated metals from tissues, blood, or organs — and different from establishing that the zeolite within Ultra Binder®’s proprietary blend produces equivalent effects. If you have documented or suspected heavy metal exposure, this requires medical evaluation, not self-directed supplementation.

Q: Can I take Ultra Binder® with my medications?
A: Not at the same time. Activated charcoal can reduce the GI absorption of medications. The appropriate separation interval depends on the specific drug; consult your pharmacist before starting. Both products should be separated from medications — the capsule label specifies 30 minutes before or 2 hours after.

Q: Is Ultra Binder® appropriate if I have mold illness?
A: Mold illness and mycotoxin exposure require medical evaluation and diagnosis. If a clinician has determined that a GI binding protocol is appropriate for your situation, discuss the evidence and this product with your pharmacist as part of that supervised protocol. Do not self-direct this use.

Q: How is a dietary supplement binder different from prescription chelation therapy?
A: Prescription chelation uses pharmaceutical agents with defined indications, dosing protocols, safety considerations, and monitoring requirements. Dietary GI binders work in the GI tract to reduce absorption of certain substances and are not equivalent to prescription chelation. They should not substitute for medically indicated treatment of diagnosed metal toxicity.

Related Clinical Insights Articles

• Renagen DTX: What the Research Shows →

Reviewed by: Dai Tran, PharmD, MBA, B.S.  View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com